MAA submitted for tivozanib for the treatment of RCC
1 March 2016 | By Victoria White
Tivozanib is an oral, once-daily, vascular endothelial growth factor (VEGF) tyrosine kinase inhibitor (TKI)...
List view / Grid view
1 March 2016 | By Victoria White
Tivozanib is an oral, once-daily, vascular endothelial growth factor (VEGF) tyrosine kinase inhibitor (TKI)...
4 June 2015 | By Victoria White
AVEO has received confirmation of support from two CHMP members following pre-submission meetings to discuss the potential submission of a MAA for tivozanib...
4 January 2012 | By Astellas
Tivozanib has demonstrated superiority over sorafenib...
1 December 2011 | By Boehringer Ingelheim
AVEO & Boehringer Ingelheim enter into an agreement...